Question of the Week & Rationale 

Our “Question of the Week” is created weekly by Coach Beverly to cover a variety of Diabetes related topics. The questions are designed to keep you current and prepare you for the CDCES® Exam.

To sign up to receive the question of the week, download our free CDCES Coach App or join our Facebook Page. 

This week’s Rationale: Question of the Week – January 16th – test your knowledge before seeing answer below! 

What a perfect way to information share and bring new concepts to light. We appreciate our community of diabetes educators and the opportunity to keep learning together! 

Question:

Semaglutide (Ozempic) is a newly approved GLP-1 Receptor Agonist with a few unique features. Which of the following statements is true about Semaglutide (Ozempic)?

1. It is available as an oral medication or injectable
2. It reduces A1c less than other GLP-1 RAs
3. It is associated with greater weight loss than other GLP-1 RAs
4. It can be administered via pump

Correct Answer: c. It is associated with greater weight loss than other GLP-1 RAs

Rationale: Semaglutide (Ozempic,) as an adjunct to diet and exercise for the treatment of type 2 diabetes in adults.

Currently only available as an injection, this once weekly (GLP-1) receptor agonist will be available in 0.5-mg and 1.0-mg doses, via a dedicated prefilled pen device. 

Semaglutide might be more effective than some of its competitors. In the five SUSTAIN efficacy trials, semaglutide reduced hemoglobin A1c by 1.5 to 1.8 percentage points. And, Semaglutide was associated with a 4.5- to 6.4-kg weight loss, more than the other available GLP-1 RAs.

For more info:

Download our updated FREE Injectables PocketCard

Or join our Medication Update webinar! 

Meds Update 2018– Earn 1.5 CE – $29

Live webinar session February 19th, 2018 at 11:30 a.m. – 1:15 p.m. PST

Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.

If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update.